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Abstract
Background: Experimental autoimmune encephalomyelitis is a widely used animal model to
understand not only multiple sclerosis but also basic principles of immunity. The disease is scored
typically by observing signs of paralysis, which do not always correspond with pathological changes.
Methods: Experimental autoimmune encephalomyelitis was induced in transgenic mice expressing
an injury responsive luciferase reporter in astrocytes (GFAP-luc). Bioluminescence in the brain and
spinal cord was measured non-invasively in living mice. Mice were sacrificed at different time points
to evaluate clinical and pathological changes. The correlation between bioluminescence and clinical
and pathological EAE was statistically analyzed by Pearson correlation analysis.
Results: Bioluminescence from the brain and spinal cord correlates strongly with severity of
clinical disease and a number of pathological changes in the brain in EAE. Bioluminescence at early
time points also predicts severity of disease.
Conclusion: These results highlight the potential use of bioluminescence imaging to monitor
neuroinflammation for rapid drug screening and immunological studies in EAE and suggest that
similar approaches could be applied to other animal models of autoimmune and inflammatory
disorders.
Background
Experimental autoimmune encephalomyelitis (EAE) is
the most commonly used animal model to study multiple
sclerosis (MS), a progressive paralytic disease character-
ized by inflammation of the central nervous system
(CNS), myelin destruction, and axonal loss [1]. EAE has
proven to be an invaluable tool for the development of
therapeutic approaches to MS. The model has also helped
in the discovery of numerous cytokines and chemokines
and the characterization of T helper cell subsets, thus play-
ing a key role in understanding basic principles of
immune function and autoimmunity [2]. Disease onset
and severity of EAE is typically assessed by clinical evalua-
tion and less frequently by postmortem pathological
examination of the brain and spinal cord. The active
lesion in EAE is characterized by a perivascular and paren-
chymal inflammatory response comprising infiltrated
lymphocytes and macrophages as well as activated micro-
glia and astrocytes. While clinical scoring is a convenient
non-invasive way to assess neurological deficits, it does
not always reflect pathological changes or provide direct
information about cellular or molecular processes [3]. On
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animals, which can then not be followed anymore, lead-
ing to large cohorts and making it often difficult to study
disease modifiers with subtle effects.
Bioluminescence imaging has been used recently to mon-
itor and quantify gene activity repeatedly in the same ani-
mal and to study disease progression in peripheral organs
with great success [4,5]. Bioluminescence imaging is
quantitative and can faithfully report gene activation if
appropriate promoter elements are used [6,7]. To gain
molecular information in living mice about the CNS
injury response in EAE, we took advantage of the fact that
astrocytes react to CNS injury by increasing the transcrip-
tion of glial fibrillary acidic protein (GFAP) [8]. Increased
GFAP immunoreactivity coincides with onset of clinical
symptoms and inflammation in acute EAE [9], and
increased GFAP mRNA levels correlate with EAE symp-
toms in acute [10] and chronic relapsing EAE [11]. To
quantify GFAP transcriptional responses in vivo we used
GFAP-luciferase (GFAP-luc) transgenic mice expressing
luciferase under the transcriptional control of the mouse
GFAP promoter [12]. These mice have been previously
used to demonstrate activation of the reporter after kain-
ate injury [12] or to monitor host response in a mouse
model of meningitis [13], but no correlation with brain
injury or neuropathology was reported.
Methods
Mice
GFAP-luc mice [12], originally generated on the FVB/N
genetic background, were crossed with C57BL/6J-Tyrc-2J
and F1 offspring were used for experiments. Mice were
between 8 and 12 weeks of age when experiments were
initiated. Animal handling was performed in accordance
with institutional guidelines and approved by the local
IACUC.
EAE induction and clinical assessment
MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) was
synthesized by the Stanford Protein and Nucleic Acid Bio-
technology Facility and purified by high-performance liq-
uid chromatography to greater than 95% purity. Mice
were immunized subcutaneously with 100 µg of MOG35–
55 peptide emulsified in complete Freund's adjuvant
(CFA) and received an intravenous (i.v.) injection of 400
ng of pertussis toxin (List Biological Laboratories, Inc.,
Campbell, CA), at the time of immunization and 48 h
later. Mice were examined daily for clinical signs of EAE
and scored as follows: 0, no paralysis; 1, loss of tail tone;
2, hindlimb weakness; 3, hindlimb paralysis; 4, hindlimb
and forelimb paralysis; 5, moribund or dead.
Bioluminescence imaging
Bioluminescence was detected with the In Vivo Imaging
System 100 (IVIS; Xenogen, Alameda, CA) [14,15] which
consists of a cooled charged coupled device (CCD) cam-
era mounted on a dark box. Mice were injected intraperi-
toneally with 150 mg/kg D-luciferin (Xenogen) 10 min
before imaging and anesthetized with isofluorane during
imaging. Imaging signal was quantitated as photons/s/
cm2/steridian (sr) using LIVINGIMAGE software (version
2.50) (Xenogen) and integrated over 3 min. For signal
quantification, photons were obtained from a region of
interest which was kept constant in area and positioning
within all experiments. For longitudinal comparison of
bioluminescence, baseline imaging was performed 24 h
before EAE was initiated. Bioluminescence was expressed
as fold induction over baseline levels. In addition, a back-
ground bioluminescence reading obtained in non-trans-
genic mice injected with D-luciferin was subtracted from
all values.
Tissue preparations
Mice were anesthetized with 400 mg/kg chloral hydrate
(Sigma-Aldrich) and transcardially perfused with 0.9%
saline. Brains and spinal cords were removed and fixed for
24 h in 4% paraformaldehyde and cryoprotected in 30%
sucrose. Brains were sectioned sagittally and spinal cords
were cut transversely at 40 µm using a freezing microtome
(Leica, Allendale, NJ) and stored in cryoprotective
medium.
Immunohistochemistry
Immunohistochemistry was performed on free-floating
sections following standard procedures [15]. Primary
antibodies were against: GFAP (1:1000, Dako, Carpinte-
ria, CA), CD68 (1:50, Serotec, Raleigh, NC), and CD4
(1:100; BD Biosciences, San Diego, CA). Primary anti-
body staining against CD68 and CD4 was revealed using
biotinylated secondary antibodies and the ABC kit (Vec-
tor, Burlingame, CA) with Diaminobenzidine (DAB,
Sigma-Aldrich). Primary antibody staining against GFAP
was revealed using fluorescent secondary antibody. Quan-
tification of the percent area covered by immunostaining
was performed by Metamorph software (Molecular
Devices, Sunnyvale, CA) [15].
Statistical analysis
Data were expressed as mean ± SEM. Statistical analyses
were performed with Prism 4.03 software (GraphPad Soft-
ware, San Diego, CA). Correlation coefficients were calcu-
lated using Pearson correlation analyses.
Results and discussion
To develop a model for simple non-invasive imaging of
EAE we used a reporter mouse in which the injury-respon-
sive GFAP promoter is fused to luciferase [12]. GFAP-lucPage 2 of 6
(page number not for citation purposes)
Journal of Neuroinflammation 2008, 5:6 http://www.jneuroinflammation.com/content/5/1/6mice were originally generated on the FVB/N genetic back-
ground and although these mice develop relapsing EAE
with full-length myelin basic protein [16] or MOG1–25
[17] they did not develop comparable EAE with the H2d
restricted MOG35–55 epitope in our initial experiment
(data not shown). We therefore crossed GFAP-luc mice
first with C57BL/6J-Tyrc-2J and F1 offspring was used in all
experiments herein. We immunized these mice with
MOG35–55 emulsified in complete Freund's adjuvant
(CFA) and pertussis toxin (PT). A typical clinical course
was established and all immunized mice developed EAE.
The first clinical signs appeared 10.5 ± 0.3 days post-
immunization (dpi). Clinical scores reached a peak at 14
± 2.6 dpi and the average duration of the peak was 6.8 ±
1.9 days.
Intraperitoneal injection of luciferin into immunized
GFAP-luc mice resulted in a small but detectable increase
in bioluminescence in the brain as early as 3 dpi and to a
significant increase at 7 dpi (Figure 1A). Importantly,
mice did not show any clinical signs of disease until 11
dpi (Figure 1B), consistent with rapid activation of astro-
cytes during EAE and astrocyte activation preceding clini-
cal manifestations by several days [10,18]. Similar results
Bioluminescence imaging of GFAP-dependent transcription in EAEF g re 1
Bioluminescence imaging of GFAP-dependent transcription in EAE. EAE was induced in GFAP-luc mice with MOG35–55 emulsi-
fied in CFA plus pertussis toxin and bioluminescence was recorded in living mice injected with luciferin (150 mg/kg) 1 day 
before (-1) and at indicated time points after immunization. (a) Time course of bioluminescence recorded in a representative 
mouse. (b) Bioluminescence was expressed as fold induction and plotted with clinical score (n = 23). (c) Time course of EAE-
associated neuropathology. GFAP-luc mice were sacrificed at indicated time points. Neuroinflammation was assessed by immu-
nohistochemistry as a function of astrogliosis (GFAP), microgliosis (CD68) and T lymphocyte infiltration (CD4). Scale bar = 
100 µm.Page 3 of 6
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bioluminescence signal in both the brain and spinal cord
peaked around 14 dpi and slowly declined throughout
the remainder of the time course, with several-fold
increases over baseline still detected at 35 dpi. As
expected, none of the animals injected with CFA or PT
alone developed clinical EAE disease and no significant
increase of bioluminescence was observed (Figure 2).
Overall, the relative changes in bioluminescence meas-
ured over the brain or spinal cord in immunized mice cor-
related strongly and significantly with clinical scores and
weight loss (Table 1). These results show that GFAP-
dependent reporter gene activity precedes clinical signs
and can be used as a simple surrogate marker to monitor
disease onset and progression in EAE.
To determine whether luciferase reporter activity is also an
indicator of neuropathological changes, GFAP-luc mice
were evaluated for clinical signs of EAE, imaged for biolu-
minescence, and sacrificed at 3- to 7-day intervals during
the course of EAE. Immunostaining of brain and spinal
cord sections with established markers of neuroinflam-
mation revealed typical pathological signs (Figure 1C).
Activation of astrocytes (GFAP) and microglia (CD68)
was observed as early as 3–7 dpi in the spinal cord, several
days before clinical symptoms appear, and peaked at 14
dpi, consistent with bioluminescence imaging (Figure
1B). Indeed, bioluminescence in brain and spinal cord
correlated remarkably well with astrogliosis and micro-
gliosis (Table 1). Bioluminescence also correlated with
CD4+ T cell infiltration although significant T cell num-
bers were not seen until 10 dpi, immediately before clini-
cal symptoms were noticeable (Figure 1C).
While clinical scores correlated strongly with weight loss,
correlations were weaker with astrogliosis and microglio-
sis (Table 2). The advantage of using GFAP-luciferase
dependent bioluminescence imaging over clinical scoring




R P R P
Astrogliosis (GFAP) 0.700 0.0001 0.817 < 0.0001
Microgliosis (CD68) 0.642 0.0007 0.803 < 0.0001
T cell infiltration (CD4) 0.784 < 0.0001 0.855 < 0.0001
Weight loss R = 0.855; P = 0.0001
GFAP-luc mice were immunized with MOG35–55 emulsified in CFA 
plus pertussis toxin. Mice were evaluated daily for clinical signs. 
Bioluminescence was recorded in living mice and expressed as fold 
induction over baseline measured 1 day before immunization. 
Neuroinflammation was measured by immunolabeling for GFAP 
(astrogliosis), CD68 (microgliosis) and CD4 (T cell infiltration). 
These markers were quantified separately in brain (cerebellum) and 
spinal cord using Metamorph image analysis software. The 
correlation between these markers and corresponding clinical score 
was assessed by Pearson correlation analysis (n = 23 mice). R: 
correlation coefficient.
Astrocyte activation in response to adjuvant or MOG35–55 peptideFigur  2
Astrocyte activation in response to adjuvant or MOG35–55 
peptide. GFAP-luc mice were injected with PBS, CFA, PT, 
MOG35–55 peptide or combinations. Bioluminescence was 
recorded in living mice 1 day before and day 14 after injec-
tion and expressed as fold induction over baseline. Bars are 
mean ± SEM (n = 3–4 mice per group). *: P < 0.01 as com-
pared with PBS by ANOVA and Tukey's post-hoc test.




R P R P
Clinical score 0.715 < 0.0001 0.868 < 0.0001
Weight loss 0.701 0.0001 0.813 < 0.0001
Astrogliosis (GFAP) 0.801 < 0.0001 0.858 < 0.0001
Microgliosis (CD68) 0.844 < 0.0001 0.828 < 0.0001
T cell infiltration (CD4) 0.831 < 0.0001 0.855 < 0.0001
GFAP-luc mice were immunized with MOG35–55 emulsified in CFA 
plus pertussis toxin. Mice were evaluated for clinical signs and 
sacrificed at 3- to 7-day interval (n = 3–8 mice at each time point; n = 
23 mice in total). Bioluminescence was recorded in living mice after 
immunization and expressed as fold induction over baseline measured 
1 day before immunization. Neuroinflammation was measured by 
immunolabeling for GFAP (astrogliosis), CD68 (microgliosis) and CD4 
(T cell infiltration). These markers were quantified separately in brain 
(cerebellum) and spinal cord using Metamorph image analysis 
software. The correlation between these markers and corresponding 
bioluminescence was assessed by Pearson correlation analyses. R: 
correlation coefficient.Page 4 of 6
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Thus, bioluminescence showed highly significant correla-
tions with glial cell activation during the first 10 days of
the disease while clinical scores did not correlate at all
(Table 3). Moreover, bioluminescence but not clinical
scores at early time points could predict peak clinical
scores. For example, bioluminescence at 10 dpi was highly
predictive of disease severity at day 14, typically the peak
of disease (Figure 3).
These findings are consistent with previous reports that
activation of astrocytes and increased GFAP mRNA levels
correlate with EAE symptoms [10,11] and highlight the
usefulness of bioluminescence imaging to monitor neu-
roinflammation in EAE and related animal models of
inflammatory disorders. However, since the correlation of
GFAP increase with long-term neurological deficits such
as demyelination and neurodegeneration is not well
established, it remains to be determined whether biolu-
minescence imaging can be applied for the study of these
aspects of disease as well.
In summary, our study describes a new method of in vivo
bioluminescence imaging to monitor and quantify neu-
roinflammation in an experimental mouse model of MS.
There are still very few studies using bioluminescent
reporters to image biological processes or disease in the
brain. We recently reported the use of a minimal reporter
for Smad2/3 transcription factor dependent signaling
(SBE-luc) to monitor and quantify activation of a luci-
ferase reporter gene in the brain [15]. We showed that the
SBE-luc reporter gene is responsive to kainate injury and
that the extent of activation correlates strongly with neu-
ronal damage and microglial activation [15]. We also used
GFAP-luc and SBE-luc mice recently to show that glial
TGF-β signaling is activated early in EAE and may pro-
mote disease independent of autoimmune T cells [19].
These results, together with the current findings demon-
strate that injury responsive genes can function as surro-
gate markers of brain injury and can be used to track and
monitor disease progression in the brain. GFAP-luc mice
should accelerate the study of autoimmune responses in
EAE and neuroimmune responses in general. These and
similar reporter mice could also be useful for in vivo,
medium-throughput assessment of new therapeutic strat-
egies for the treatment of MS and neuroinflammation.
Conclusion
Bioluminescence imaging of GFAP-luc reporter mice pro-
vides a new tool to monitor disease onset and progression
in living mice over time. These mice should be useful for
Bioluminescence recorded at day 10 correlates strongly with clinical scor  at day 14F g re 3
Bioluminescence recorded at day 10 correlates strongly with 
clinical score at day 14. GFAP-luc mice were immunized with 
MOG35–55 emulsified in CFA plus pertussis toxin. Biolumines-
cence was recorded in living mice and expressed as fold 
induction over baseline measured 1 day before immunization. 
Each dot represents one mouse. The correlation was 
assessed by Pearson correlation analysis (n = 10 mice). R: 
correlation coefficient.
Table 3: Clinical score does not correlate with pathology in the early stages of disease (day 1–10).
Bioluminescence (fold induction) Clinical score
Brain Spinal cord Brain Spinal cord
R P R P R P R P
Astrogliosis (GFAP) 0.704 0.015 0.713 0.010 0.120 0.298 0.233 0.501
Microgliosis (CD68) 0.886 <0.0001 0.478 0.141 0.352 0.298 0.040 0.914
T cell infiltration (CD4) 0.549 0.081 0.774 0.004 0.388 0.247 0.472 0.147
Weight loss 0.823 0.0001 0.811 0.0001 R = 0.354; P = 0.286
Bioluminescence correlates with disease progression in the early stage (day 1–10), but clinical score does not. GFAP-luc mice were immunized with 
MOG35–55 emulsified in CFA plus pertussis toxin. Mice were evaluated for clinical signs and bioluminescence and sacrificed at day 3, 5, 7 and 10 (n = 
11 mice). The same mice were part of the analysis shown in Table 1. The correlation was analyzed by Pearson correlation analysis. R: correlation 
coefficient.Page 5 of 6
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